Staphylococcus Aureus Infection Differential Diagnoses

1. Jamal N, Teach SJ. Necrotizing fasciitis. Pediatr Emerg Care. 2011 Dec. 27(12):1195-9; quiz 1200-2. [QxMD MEDLINE Link].

2. Jaramillo D. Infection: musculoskeletal. Pediatr Radiol. 2011 May. 41 Suppl 1:S127-34. [QxMD MEDLINE Link].

3. Chou H, Teo HE, Dubey N, Peh WC. Tropical pyomyositis and necrotizing fasciitis. Semin Musculoskelet Radiol. 2011 Nov. 15(5):489-505. [QxMD MEDLINE Link].

4. Lane JW, Tang J, Taggard D, Byun R. Successful use of daptomycin and linezolid, without surgical intervention, in the treatment of extensive epidural abscess and bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA). Infect Dis Clin Pract. Sept 2011. 19(5):362-364.

5. Abdel-Haq N, Quezada M, Asmar BI. Retropharyngeal Abscess in Children: The Rising Incidence of Methicillin-Resistant Staphylococcus aureus. Pediatr Infect Dis J. 2012 Jul. 31(7):696-9. [QxMD MEDLINE Link].

6. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus Infections in Pediatric Oncology Patients: High Rates of Antimicrobial Resistance, Antiseptic Tolerance and Complications. Pediatr Infect Dis J. 2012 Sep 11. [QxMD MEDLINE Link].

7. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R. Empiric Antimicrobial Therapy for Pediatric Skin and Soft-Tissue Infections in the Era of Methicillin-Resistant Staphylococcus aureus. Pediatrics. 2009 Jun. 123(6):e959-66. [QxMD MEDLINE Link].

8. Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?. Antimicrob Agents Chemother. 2011 Nov. 55(11):5122-6. [QxMD MEDLINE Link]. [Full Text].

9. Williams DJ, Cooper WO, Kaltenbach LA, Dudley JA, Kirschke DL, Jones TF, et al. Comparative Effectiveness of Antibiotic Treatment Strategies for Pediatric Skin and Soft-Tissue Infections. Pediatrics. 2011 Aug 15. [QxMD MEDLINE Link].

10. [Guideline] Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clin Infect Dis. 2011 Feb 1. 52(3):e18-e55. [QxMD MEDLINE Link].

11. Kemper AR, Dolor RJ, Fowler VG Jr. Management of skin abscesses by primary care pediatricians. Clin Pediatr (Phila). 2011 Jun. 50(6):525-8. [QxMD MEDLINE Link].

12. Sreeramoju P, Porbandarwalla NS, Arango J, Latham K, Dent DL, Stewart RM, et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg. 2011 Feb. 201(2):216-20. [QxMD MEDLINE Link].

13. Pääkkönen M, Kallio PE, Kallio MJ, Peltola H. Management of Osteoarticular Infections Caused by Staphylococcus aureus Is Similar to That of Other Etiologies: Analysis of 199 Staphylococcal Bone and Joint Infections. Pediatr Infect Dis J. 2012 May. 31(5):436-8. [QxMD MEDLINE Link].

14. Boggs W. Daptomycin Treats S. aureus Bacteremia Without Nephrotoxicity. Medscape Medical News. January 8, 2013. Available at http://www.medscape.com/viewarticle/777276. Accessed: January 15, 2013.

15. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4. 344(1):11-6. [QxMD MEDLINE Link].

16. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL. Reclassification of Staphylococcus aureus Nasal Carriage Types. J Infect Dis. 2009 Jun 15. 199(12):1820-6. [QxMD MEDLINE Link].

17. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 1995 Sep. 31(1):13-24. [QxMD MEDLINE Link].

18. Ruimy R, Angebault C, Djossou F, et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans?. J Infect Dis. 2010 Sep 15. 202(6):924-34. [QxMD MEDLINE Link].

19. Chen CJ, Hsu KH, Lin TY, Hwang KP, Chen PY, Huang YC. Factors associated with nasal colonization of methicillin-resistant Staphylococcus aureus among healthy children in Taiwan. J Clin Microbiol. 2011 Jan. 49(1):131-7. [QxMD MEDLINE Link]. [Full Text].

20. Nerby JM, Gorwitz R, Lesher L, Juni B, Jawahir S, Lynfield R. Risk Factors for Household Transmission of Community-associated Methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2011 Nov. 30(11):927-32. [QxMD MEDLINE Link].

21. Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J, Dunne WM, et al. The natural history of contemporary Staphylococcus aureus nasal colonization in community children. Pediatr Infect Dis J. 2011 Apr. 30(4):349-51. [QxMD MEDLINE Link]. [Full Text].

22. Gesualdo F, Bongiorno D, Rizzo C, Bella A, Menichella D, Stefani S, et al. MRSA Nasal Colonization in Children: Prevalence Meta-Analysis, Review of Risk Factors and Molecular Genetics. Pediatr Infect Dis J. 2013 Jan 21. [QxMD MEDLINE Link].

23. Peters PJ, Brooks JT, McAllister SK, Limbago V, Lowery HK, Fosheim G, et al. Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults. Emerg Infect Dis. April 2013. 19(4):623-629.

24. Faden H, Lesse AJ, Trask J, Hill JA, Hess DJ, Dryja D. Importance of Colonization Site in the Current Epidemic of Staphylococcal Skin Abscesses. Pediatrics. 2010 Feb 15. [QxMD MEDLINE Link].

25. Lee CJ, Sankaran S, Mukherjee DV, Apa ZL, Hafer CA, Wright L. Staphylococcus aureus oropharyngeal carriage in a prison population. Clin Infect Dis. 2011 Mar 15. 52(6):775-8. [QxMD MEDLINE Link].

26. Nowrouzian FL, Dauwalder O, Meugnier H, Bes M, Etienne J, Vandenesch F, et al. Adhesin and Superantigen Genes and the Capacity of Staphylococcus aureus to Colonize the Infantile Gut. J Infect Dis. 2011 Sep. 204(5):714-21. [QxMD MEDLINE Link].

27. Milstone AM, Song X, Coffin S, Elward A. Identification and eradication of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit: results of a national survey. Infect Control Hosp Epidemiol. 2010 Jul. 31(7):766-8. [QxMD MEDLINE Link]. [Full Text].

28. Nakamura MM, McAdam AJ, Sandora TJ, Moreira KR, Lee GM. Higher prevalence of pharyngeal than nasal Staphylococcus aureus carriage in pediatric intensive care units. J Clin Microbiol. 2010 Aug. 48(8):2957-9. [QxMD MEDLINE Link].

29. Matheson EM, Mainous AG 3rd, Everett CJ, King DE. Tea and coffee consumption and MRSA nasal carriage. Ann Fam Med. 2011 Jul-Aug. 9(4):299-304. [QxMD MEDLINE Link].

30. Zanger P, Nurjadi D, Gaile M, Gabrysch S, Kremsner PG. Hormonal Contraceptive Use and Persistent Staphylococcus aureus Nasal Carriage. Clin Infect Dis. 2012 Dec. 55(12):1625-32. [QxMD MEDLINE Link].

31. Bartlett AH, Hulten KG. Staphylococcus aureus pathogenesis: secretion systems, adhesins, and invasins. Pediatr Infect Dis J. 2010 Sep. 29(9):860-1. [QxMD MEDLINE Link].

32. Tuchscherr L, Heitmann V, Hussain M, Viemann D, Roth J, von Eiff C, et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J Infect Dis. 2010 Oct 1. 202(7):1031-40. [QxMD MEDLINE Link].

33. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C. Immunogenicity of toxins during Staphylococcus aureus infection. Clin Infect Dis. 2010 Jan 1. 50(1):61-8. [QxMD MEDLINE Link].

34. Aalfs AS, Oktarina DA, Diercks GF, Jonkman MF, Pas HH. Staphylococcal scalded skin syndrome: loss of desmoglein 1 in patient skin. Eur J Dermatol. 2010 Jul-Aug. 20(4):451-6. [QxMD MEDLINE Link].

35. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice?. Int J Antimicrob Agents. 2009 Jul. 34 Suppl 1:S15-9. [QxMD MEDLINE Link].

36. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010 Jul. 23(3):616-87. [QxMD MEDLINE Link].

37. Pickett A, Wilkinson M, Menoch M, Snell J, Yniguez R, Bulloch B. Changing incidence of methicillin-resistant staphylococcus aureus skin abscesses in a pediatric emergency department. Pediatr Emerg Care. 2009 Dec. 25(12):831-4. [QxMD MEDLINE Link].

38. Kairam N, Silverman ME, Salo DF, Baorto E, Lee B, Amato CS. Cutaneous Methicillin-Resistant Staphylococcus aureus in a Suburban Community Hospital Pediatric Emergency Department. J Emerg Med. 2011 Nov. 41(5):460-5. [QxMD MEDLINE Link].

39. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008 Jun 1. 46 Suppl 5:S344-9. [QxMD MEDLINE Link].

40. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009 Sep. 64(3):441-6. [QxMD MEDLINE Link].

41. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, et al. Comparison of Staphylococcus aureus From Skin and Soft-Tissue Infections in US Emergency Department Patients, 2004 and 2008. Clin Infect Dis. 2011 Jul. 53(2):144-149. [QxMD MEDLINE Link].

42. Long CB, Madan RP, Herold BC. Diagnosis and management of community-associated MRSA infections in children. Expert Rev Anti Infect Ther. 2010 Feb. 8(2):183-95. [QxMD MEDLINE Link].

43. Lowy FD. How Staphylococcus aureus adapts to its host. N Engl J Med. 2011 May 26. 364(21):1987-90. [QxMD MEDLINE Link].

44. Hay R, Noor NM. Panton-Valentine leucocidin and severe Staphylococcus aureus infections of the skin: sole culprit or does it have accomplices?. Curr Opin Infect Dis. 2011 Apr. 24(2):97-9. [QxMD MEDLINE Link].

45. Ritz N, Curtis N. The Role of Panton-Valentine Leukocidin in Staphylococcus aureus Musculoskeletal Infections in Children. Pediatr Infect Dis J. 2012 May. 31(5):514-8. [QxMD MEDLINE Link].

46. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia. J Clin Microbiol. 2012 Nov. 50(11):3694-702. [QxMD MEDLINE Link]. [Full Text].

47. Hermos CR, Yoong P, Pier GB. High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin Infect Dis. 2010 Nov 15. 51(10):1138-46. [QxMD MEDLINE Link].

48. Grundmeier M, Tuchscherr L, Bruck M, Viemann D, Roth J, Willscher E. Staphylococcal strains vary greatly in their ability to induce an inflammatory response in endothelial cells. J Infect Dis. 2010 Mar 15. 201(6):871-80. [QxMD MEDLINE Link].

49. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA, Kranz DM, Schlievert PM. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis. 2010 Dec 1. 202(11):1690-7. [QxMD MEDLINE Link].

50. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis. 2010 Dec 15. 202(12):1866-76. [QxMD MEDLINE Link].

51. Torres VJ, Stauff DL, Pishchany G, Bezbradica JS, Gordy LE, Iturregui J, et al. A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe. 2007 Apr 19. 1(2):109-19. [QxMD MEDLINE Link]. [Full Text].

52. Pishchany G, McCoy AL, Torres VJ, Krause JC, Crowe JE Jr, Fabry ME, et al. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe. 2010 Dec 16. 8(6):544-50. [QxMD MEDLINE Link]. [Full Text].

53. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, et al. Comparative Analysis of USA300 Virulence Determinants in a Rabbit Model of Skin and Soft Tissue Infection. J Infect Dis. 2011 Sep. 204(6):937-41. [QxMD MEDLINE Link]. [Full Text].

54. Hota B, Lyles R, Rim J, Popovich KJ, Rice T, Aroutcheva A. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin Infect Dis. 2011 Oct. 53(8):757-65. [QxMD MEDLINE Link].

55. Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine Leukocidin gene. Clin Infect Dis. 2011 Oct. 53(8):766-71. [QxMD MEDLINE Link].

56. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD. Staphylococcus aureus a-Hemolysin Mediates Virulence in a Murine Model of Severe Pneumonia Through Activation of the NLRP3 Inflammasome. J Infect Dis. 2012 Mar. 205(5):807-17. [QxMD MEDLINE Link].

57. Rudkin JK, Edwards AM, Bowden MG, Brown EL, Pozzi C, Waters EM. Methicillin Resistance Reduces the Virulence of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus by Interfering With the agr Quorum Sensing System. J Infect Dis. 2012 Mar. 205(5):798-806. [QxMD MEDLINE Link].

58. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, et al. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar. 50(3):848-56. [QxMD MEDLINE Link]. [Full Text].

59. Soong G, Chun J, Parker D, Prince A. Staphylococcus aureus Activation of Caspase 1/Calpain Signaling Mediates Invasion Through Human Keratinocytes. J Infect Dis. 2012 May. 205(10):1571-9. [QxMD MEDLINE Link].

60. Otto M. How Staphylococcus aureus Breaches Our Skin to Cause Infection. J Infect Dis. 2012 May. 205(10):1483-5. [QxMD MEDLINE Link].

61. Wehrhahn MC, Robinson JO, Pascoe EM, Coombs GW, Pearson JC, O'Brien FG. Illness Severity in Community-Onset Invasive Staphylococcus aureus Infection and the Presence of Virulence Genes. J Infect Dis. 2012 Jun. 205(12):1840-8. [QxMD MEDLINE Link].

62. Garofalo A, Giai C, Lattar S, Gardella N, Mollerach M, Kahl BC. The Length of the Staphylococcus aureus Protein A Polymorphic Region Regulates Inflammation: Impact on Acute and Chronic Infection. J Infect Dis. 2012 Jul. 206(1):81-90. [QxMD MEDLINE Link].

63. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2013 Jan. 13(1):43-54. [QxMD MEDLINE Link]. [Full Text].

64. Suryadevara M, Clark AE, Wolk DM, Carman A, Rosenbaum PF. Molecular characterization of invasive Staphylococcus aureus infection in central New York children: importance of two clonal groups and inconsistent presence of selected virulence determinants. J Pediatr Infect Dis Soc. March 2013. 2(1):30-39.

65. Schneider-Lindner V, Quach C, Hanley JA, Suissa S. Antibacterial Drugs and the Risk of Community-Associated Methicillin-Resistant Staphylococcus aureus in Children. Arch Pediatr Adolesc Med. 2011 Aug 1. [QxMD MEDLINE Link].

66. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999 Feb 18. 340(7):493-501. [QxMD MEDLINE Link].

67. Zheng X, Qi C, Arrieta M, O'Leary A, Wang D, Shulman ST. Lack of increase in vancomycin resistance of pediatric methicillin-resistant Staphylococcus aureus Isolates from 2000 to 2007. Pediatr Infect Dis J. 2010 Sep. 29(9):882-4. [QxMD MEDLINE Link].

68. Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC Jr, Eliopoulos GM. Serine/Threonine Phosphatase Stp1 Contributes to Reduced Susceptibility to Vancomycin and Virulence in Staphylococcus aureus. J Infect Dis. 2012 Jun. 205(11):1677-87. [QxMD MEDLINE Link].

69. Cheung A, Duclos B. Stp1 and Stk1: The Yin and Yang of Vancomycin Sensitivity and Virulence in Vancomycin-Intermediate Staphylococcus aureus Strains. J Infect Dis. 2012 Jun. 205(11):1625-7. [QxMD MEDLINE Link].

70. Shore AC, Deasy EC, Slickers P, et al. Detection of Staphylococcal Cassette Chromosome mec Type XI Encoding Highly Divergent mecA, mecI, mecR1, blaZ and ccr Genes in Human Clinical Clonal Complex 130 Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Jun 2. [QxMD MEDLINE Link].

71. García-Álvarez L, Holden MT, Lindsay H, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011 Jun 2. [QxMD MEDLINE Link].

72. Cameron DR, Howden BP, Peleg AY. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis. 2011 Sep. 53(6):576-82. [QxMD MEDLINE Link].

73. [Guideline] CDC. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997 Jul 11. 46(27):626-8, 635. [QxMD MEDLINE Link].

74. Iwamoto M, Mu Y, Lynfield R, Bulens SN, Nadle J, Aragon D, et al. Trends in Invasive Methicillin-Resistant Staphylococcus aureus Infections. Pediatrics. 2013 Oct. 132(4):e817-e824. [QxMD MEDLINE Link].

75. Laidman J. Community-Associated MRSA Incidence on the Rise in Children. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/811483. Accessed: September 30, 2013.

76. Helwick C. MRSA Rising in Children With Musculoskeletal Infections. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/813484. Accessed: November 4, 2013.

77. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012 Aug. 55(4):582-6. [QxMD MEDLINE Link].

78. Frei CR, Makos BR, Daniels KR, Oramasionwu CU. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. J Pediatr Surg. 2010 Oct. 45(10):1967-74. [QxMD MEDLINE Link].

79. Hadler JL, Petit S, Mandour M, Cartter ML. Trends in Invasive Infection with Methicillin-Resistant Staphylococcus aureus, Connecticut, USA, 2001-2010. Emerg Infect Dis. 2012 Jun. 18(6):917-24. [QxMD MEDLINE Link]. [Full Text].

80. Suryadevara M, Moro MR, Rosenbaum PF, Kiska D, Riddell S, Weiner LB. Incidence of invasive community-onset Staphylococcus aureus infections in children in Central New York. J Pediatr. 2010 Jan. 156(1):152-154.e1. [QxMD MEDLINE Link].

81. Landrum ML, Neumann C, Cook C, Chukwuma U, Ellis MW, Hospenthal DR. Epidemiology of Staphylococcus aureus Blood and Skin and Soft Tissue Infections in the US Military Health System, 2005-2010Staphylococcus aureus in US Military. JAMA. 2012 Jul 4. 308(1):50-9. [QxMD MEDLINE Link].

82. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, et al. Epidemiologic similarities in pediatric community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus in the San Francisco Bay area. J Pediatr Infect Dis Soc. September 2012. 1(3):200-211.

83. Reyes J, Rincon S, Diaz L, et al. Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis. 2009 Dec 15. 49(12):1861-7. [QxMD MEDLINE Link]. [Full Text].

84. Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population. Pediatrics. 2016 Mar 1. [QxMD MEDLINE Link].

85. Smit J, Søgaard M, Schønheyder HC, Nielsen H, Frøslev T, Thomsen RW. Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: A population-based case-control study. Eur J Endocrinol. 2016 Mar 10. [QxMD MEDLINE Link].

86. Davenport L. Diabetes Patients at Higher Risk of S aureus Blood Infection. Medscape Medical News. Available at http://www.medscape.com/viewarticle/860376. March 15, 2016; Accessed: April 27, 2016.

87. Saxena S, Thompson P, Birger R, Bottle A, Spyridis N, Wong I. Increasing Skin Infections and Staphylococcus aureus Complications in Children, England, 1997-2006. Emerg Infect Dis. 2010 Mar. 16(3):530-533. [QxMD MEDLINE Link].

88. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010 Apr. 10(4):227-239. [QxMD MEDLINE Link].

89. Lessa FC, Mu Y, Davies J, Murray M, Lillie M, Pearson A. Comparison of incidence of bloodstream infection with methicillin-resistant Staphylococcus aureus between England and United States, 2006-2007. Clin Infect Dis. 2010 Oct 15. 51(8):925-8. [QxMD MEDLINE Link].

90. Golding GR, Levett PN, McDonald RR, Irvine J, Quinn B, Nsungu M. High rates of Staphylococcus aureus USA400 infection, Northern Canada. Emerg Infect Dis. 2011 Apr. 17(4):722-5. [QxMD MEDLINE Link].

91. Golding GR, Levett PN, McDonald RR, Irvine J, Nsungu M, Woods S, et al. A comparison of risk factors associated with community-associated methicillin-resistant and -susceptible Staphylococcus aureus infections in remote communities. Epidemiol Infect. 2010 May. 138(5):730-7. [QxMD MEDLINE Link].

92. Kim J, Ferrato C, Golding GR, Mulvey MR, Simmonds KA, Svenson LW, et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Alberta, Canada: population-based surveillance, 2005-2008. Epidemiol Infect. 2010 Sep 21. 1-10. [QxMD MEDLINE Link].

93. Matlow A, Forgie S, Pelude L, Embree J, Gravel D, Langley JM, et al. National surveillance of methicillin-resistant Staphylococcus aureus among hospitalized pediatric patients in Canadian acute care facilities, 1995-2007. Pediatr Infect Dis J. 2012 Aug. 31(8):814-20. [QxMD MEDLINE Link].

94. Alesana-Slater J, Ritchie SR, Heffernan H, Camp T, Richardson A, Herbison P. Methicillin-resistant Staphylococcus aureus, Samoa, 2007-2008. Emerg Infect Dis. 2011 Jun. 17(6):1023-9. [QxMD MEDLINE Link].

95. Suzuki M, Yamada K, Nagao M, Aoki E, Matsumoto M, Hirayama T, et al. Antimicrobial Ointments and Methicillin-Resistant Staphylococcus aureus USA300. Emerg Infect Dis. 2011 Oct. 17(10):1917-20. [QxMD MEDLINE Link].

96. Tong SY, Bishop EJ, Lilliebridge RA, et al. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes. J Infect Dis. 2009 May 15. 199(10):1461-70. [QxMD MEDLINE Link].

97. Salmenlinna S, Lyytikainen O, Vainio A, Myllyniemi AL, Raulo S, Kanerva M, et al. Human Cases of Methicillin-Resistant Staphylococcus aureus CC398, Finland. Emerg Infect Dis. 2010 Oct. 16(10):1626-9. [QxMD MEDLINE Link].

98. Tappe D, Schulze MH, Oesterlein A, Turnwald D, Müller A, Vogel U, et al. Panton-Valentine leukocidin-positive Staphylococcus aureus infections in returning travelers. Am J Trop Med Hyg. 2010 Oct. 83(4):748-50. [QxMD MEDLINE Link]. [Full Text].

99. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Not Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)! A Clinician's Guide to Community MRSA - Its Evolving Antimicrobial Resistance and Implications for Therapy. Clin Infect Dis. 2011 Jan. 52(1):99-114. [QxMD MEDLINE Link].

100. Nickerson EK, Wuthiekanun V, Kumar V, Amornchai P, Wongdeethai N, Chheng K. Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus Carriage in Children in Cambodia. Am J Trop Med Hyg. 2011 Feb. 84(2):313-7. [QxMD MEDLINE Link].

101. Hamdan-Partida A, Sainz-Espuñes T, Bustos-Martínez J. Characterization and persistence of Staphylococcus aureus strains isolated from the anterior nares and throats of healthy carriers in a Mexican community. J Clin Microbiol. 2010 May. 48(5):1701-5. [QxMD MEDLINE Link].

102. Muttaiyah S, Coombs G, Pandey S, Reed P, Ritchie S, Lennon D, et al. Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. J Clin Microbiol. 2010 Oct. 48(10):3470-4. [QxMD MEDLINE Link]. [Full Text].

103. Adler A, Givon-Lavi N, Moses AE, Block C, Dagan R. Carriage of community-associated methicillin-resistant Staphylococcus aureus in a cohort of infants in southern Israel: risk factors and molecular features. J Clin Microbiol. 2010 Feb. 48(2):531-8. [QxMD MEDLINE Link]. [Full Text].

104. Vaska VL, Grimwood K, Gole GA, Nimmo GR, Paterson DL, Nissen MD. Community-associated Methicillin-resistant Staphylococcus aureus Causing Orbital Cellulitis in Australian Children. Pediatr Infect Dis J. 2011 Nov. 30(11):1003-1006. [QxMD MEDLINE Link].

105. Marra F, Patrick DM, Chong M, McKay R, Hoang L, Bowie WR. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother. 2012 Dec. 56(12):6243-9. [QxMD MEDLINE Link]. [Full Text].

106. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010 Oct 15. 51(8):895-903. [QxMD MEDLINE Link].

107. Spellberg B. Skin and soft-tissue infections: modern evolution of an ancient problem. Clin Infect Dis. 2010 Oct 15. 51(8):904-6. [QxMD MEDLINE Link]. [Full Text].

108. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL. Staphylococcus aureus Pneumonia in Children in the Era of Community-acquired Methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J. 2011 Jul. 30(7):545-50. [QxMD MEDLINE Link].

109. Vander Have KL, Karmazyn B, Verma M, Caird MS, Hensinger RN, Farley FA. Community-associated methicillin-resistant Staphylococcus aureus in acute musculoskeletal infection in children: a game changer. J Pediatr Orthop. 2009 Dec. 29(8):927-31. [QxMD MEDLINE Link].

110. Fretzayas A, Moustaki M, Tsagris V, Brozou T, Nicolaidou P. MRSA blistering distal dactylitis and review of reported cases. Pediatr Dermatol. 2011 Jul-Aug. 28(4):433-5. [QxMD MEDLINE Link].

111. Carrillo-Marquez MA, Hulten KG, Hammerman W, Mason EO, Kaplan SL. USA300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. Pediatr Infect Dis J. 2009 Dec. 28(12):1076-80. [QxMD MEDLINE Link].

112. Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and Molecular Epidemiology of Staphylococcus aureus Catheter-Related Bacteremia in Children. Pediatr Infect Dis J. 2010 May. 29(5):410-4. [QxMD MEDLINE Link].

113. Jacobson JA, Kasworm E, Daly JA. Risk of developing toxic shock syndrome associated with toxic shock syndrome toxin 1 following nongenital staphylococcal infection. Rev Infect Dis. 1989 Jan-Feb. 11 Suppl 1:S8-13. [QxMD MEDLINE Link].

114. John CC, Niermann M, Sharon B, Peterson ML, Kranz DM, Schlievert PM. Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis. 2009 Dec 15. 49(12):1893-6. [QxMD MEDLINE Link]. [Full Text].

115. Ramirez-Schrempp D, Dorfman DH, Baker WE, Liteplo AS. Ultrasound soft-tissue applications in the pediatric emergency department: to drain or not to drain?. Pediatr Emerg Care. 2009 Jan. 25(1):44-8. [QxMD MEDLINE Link].

116. Sivitz AB, Lam SH, Ramirez-Schrempp D, Valente JH, Nagdev AD. Effect of bedside ultrasound on management of pediatric soft-tissue infection. J Emerg Med. 2010 Nov. 39(5):637-43. [QxMD MEDLINE Link].

117. Corey GR. Staphylococcus aureus bacteremia and endocarditis: the role of diagnostic evaluation. Infect Dis Clin Pract. 2011/09. 19(5):307-312.

118. Kaasch AJ, Fowler VG Jr, Rieg S, Peyerl-Hoffmann G, Birkholz H, Hellmich M, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis. 2011 Jul 1. 53(1):1-9. [QxMD MEDLINE Link]. [Full Text].

119. Soriano A, Mensa J. Is transesophageal echocardiography dispensable in hospital-acquired Staphylococcus aureus bacteremia?. Clin Infect Dis. 2011 Jul 1. 53(1):10-2. [QxMD MEDLINE Link].

120. Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, Fernandes T, et al. Use of Transthoracic Echocardiography in the Management of Low-Risk Staphylococcus aureus Bacteremia: Results From a Retrospective Multicenter Cohort Study. JACC Cardiovasc Imaging. 2015 Jul 8. [QxMD MEDLINE Link].

121. Boggs W. Transthoracic Echocardiography Adequate for Ruling Out Infective Endocarditis. http://www.medscape.com/viewarticle/848780. Available at http://www.medscape.com/viewarticle/848780. July 30, 2015; Accessed: August 7, 2015.

122. Patel Wylie F, Kaplan SL, Mason EO, Allen CH. Needle aspiration for the etiologic diagnosis of children with cellulitis in the era of community-acquired methicillin-resistant Staphylococcus aureus. Clin Pediatr (Phila). 2011 Jun. 50(6):503-7. [QxMD MEDLINE Link].

123. Thwaites GE, Scarborough M, Szubert A,. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17. 391 (10121):668-678. [QxMD MEDLINE Link].

124. Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010 May. 55(5):401-7. [QxMD MEDLINE Link].

125. Lee MC, Rios AM, Aten MF, Mejias A, Cavuoti D, McCracken GH Jr, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004 Feb. 23(2):123-7. [QxMD MEDLINE Link].

126. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007 Nov. 51(11):4044-8. [QxMD MEDLINE Link].

127. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007 Mar 15. 44(6):777-84. [QxMD MEDLINE Link].

128. Karchmer AW. Staphylococcus aureus bacteremia and native valve endocarditis: the role of antimicrobial therapy. Infect Dis Clin Pract. March 2012. 20(2):100-108.

129. Chen AE, Carroll KC, Diener-West M, Ross T, Ordun J, Goldstein MA, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics. 2011 Mar. 127(3):e573-80. [QxMD MEDLINE Link].

130. McNamara WF, Hartin CW Jr, Escobar MA, Yamout SZ, Lau ST, Lee YH. An alternative to open incision and drainage for community-acquired soft tissue abscesses in children. J Pediatr Surg. 2011 Mar. 46(3):502-6. [QxMD MEDLINE Link].

131. Keller DM. Staph aureus Scheme Cuts Surgical Infection. Medscape Medical News. Available at http://www.medscape.com/viewarticle/833457. Accessed: October 19, 2014.

132. Schweizer M, et al. A multicenter intervention to reduce surgical site infections among patients undergoing cardiac operations and total joint arthroplasty (STOP SSI STUDY). Paper presented at IDWeek; October 8-12, 2014; Philadelphia, PA. [Full Text].

133. Smit J, López-Cortés LE, Thomsen RW, Schønheyder HC, Nielsen H, Frøslev T, et al. Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clin Proc. 2017 Oct. 92 (10):1469-1478. [QxMD MEDLINE Link].

134. Brooks M. Statins May Help Guard Against S aureus Bacteremia. Medscape News. Available at https://www.medscape.com/viewarticle/887676#vp_1. October 26, 2017; Accessed: November 1, 2017.

135. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin N Am. Dec 2009. 23(4):965-82.

136. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011 Mar. 11(3):208-222. [QxMD MEDLINE Link].

137. Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011 Aug. 128(2):271-9. [QxMD MEDLINE Link].

138. Jimenez-Truque N, Thomsen I, Saye E, Creech CB. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?. Pediatr Infect Dis J. 2010 Apr. 29(4):368-70. [QxMD MEDLINE Link].

139. Aguado JM, San-Juan R, Lalueza A, Sanz F, Rodríguez-Otero J, Gómez-Gonzalez C, et al. High Vancomycin MIC and Complicated Methicillin-Susceptible Staphylococcus aureus Bacteremia. Emerg Infect Dis. 2011 Jun. 17(6):1099-102. [QxMD MEDLINE Link].

140. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis. 2011 Apr 15. 52(8):997-1002. [QxMD MEDLINE Link].

141. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011 Apr 15. 52(8):975-81. [QxMD MEDLINE Link].

142. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011 Apr 15. 52(8):969-74. [QxMD MEDLINE Link].

143. van Hal SJ, Lodise TP, Paterson DL. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2012 Mar. 54(6):755-71. [QxMD MEDLINE Link].

144. Deresinski S. Methicillin-Resistant Staphylococcus aureus and Vancomycin: Minimum Inhibitory Concentration Matters. Clin Infect Dis. 2012 Mar. 54(6):772-4. [QxMD MEDLINE Link].

145. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clin Infect Dis. 2012 Mar. 54(5):621-9. [QxMD MEDLINE Link].

146. Ramirez P, Fernández-Barat L, Torres A. New therapy options for MRSA with respiratory infection/pneumonia. Curr Opin Infect Dis. 2012 Apr. 25(2):159-65. [QxMD MEDLINE Link].

147. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010 Mar 15. 50(6):821-5. [QxMD MEDLINE Link].

148. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010 Jun 9. 303(22):2260-4. [QxMD MEDLINE Link].

149. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13. 309(6):559-69. [QxMD MEDLINE Link].

150. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Sep. 56(9):4608-13. [QxMD MEDLINE Link]. [Full Text].

151. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13. 309(6):559-69. [QxMD MEDLINE Link].

152. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Jun 5. [QxMD MEDLINE Link].

153. Lowes, R. New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827168. Accessed: June 26, 2014.

154. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis. 2009 Dec 15. 49(12):1908-14. [QxMD MEDLINE Link].

155. Brooks M. FDA OKs Oritavancin (Orbactiv) for Skin Infections. Medscape Medical News. Aug 7 2014. [Full Text].

156. Moellering RC, Jr, Ferraro MJ. Oritavancin for the treatment of serious gram-positive infections. Clin Infect Dis. 15 April 2012. 54(Suppl 3):S201-S243.

157. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15. 51(6):641-50. [QxMD MEDLINE Link].

158. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011 May. 52(9):1156-63. [QxMD MEDLINE Link].

159. Gums JG. Ceftaroline fosamil: a broad-spectrum cephalosporin with methicillin-resistant Staphylococcus aureus activity. Infect Dis Clin Pract. March 2012. 20(2):122-130.

160. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis. 2012 Sep. 55 Suppl 3:S206-14. [QxMD MEDLINE Link].

161. Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis. 2012 Sep. 55 Suppl 3:S181-6. [QxMD MEDLINE Link].

162. Jones RN, Mendes RE, Sader HS, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S477-86. [QxMD MEDLINE Link].

163. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S520-6. [QxMD MEDLINE Link].

164. Fernandes P, Pereira D. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis. 2011 Jun. 52 Suppl 7:S542-6. [QxMD MEDLINE Link].

165. Lee AS, Macedo-Vinas M, François P, Renzi G, Schrenzel J, Vernaz N. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis. 2011 Jun 15. 52(12):1422-30. [QxMD MEDLINE Link].

166. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011 Apr 14. 364(15):1419-30. [QxMD MEDLINE Link].

167. Robotham JV, Graves N, Cookson BD, Barnett AG, Wilson JA, Edgeworth JD. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011. 343:d5694. [QxMD MEDLINE Link].

168. Simor AE. Staphylococcal decolonisation: an effective strategy for prevention of infection?. Lancet Infect Dis. 2011 Dec. 11(12):952-62. [QxMD MEDLINE Link].

169. Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Epplin EK, et al. Household Versus Individual Approaches to Eradication of Community-Associated Staphylococcus aureus in Children: A Randomized Trial. Clin Infect Dis. 2012 Mar. 54(6):743-51. [QxMD MEDLINE Link]. [Full Text].

170. Miller LG. Where We Are With Community-Associated Staphylococcus aureus Prevention--And in the Meantime, What Do We Tell Our Patients?. Clin Infect Dis. 2012 Mar. 54(6):752-4. [QxMD MEDLINE Link].

171. Kling J. PCR screening cuts in-hospital infection. Medscape Medical News. May 14, 2013. [Full Text].

172. Milstone AM, Goldner BW, Ross T, Shepard JW, Carroll KC, Perl TM. Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission. Clin Infect Dis. 2011 Nov. 53(9):853-9. [QxMD MEDLINE Link]. [Full Text].

173. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al. Targeted versus Universal Decolonization to Prevent ICU Infection. N Engl J Med. 2013 May 29. [QxMD MEDLINE Link].

174. Edmond MB, Wenzel RP. Screening Inpatients for MRSA - Case Closed. N Engl J Med. 2013 May 29. [QxMD MEDLINE Link].

175. Laidman J. MRSA: Universal Decolonization Beats Screening and Isolation. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805005. Accessed: June 11, 2013.

176. Shenoy ES, Kim J, Rosenberg ES, Cotter JA, Lee H, Walensky RP, et al. Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus: A Randomized Controlled Trial Comparing Passive and Active Screening With Culture and Polymerase Chain Reaction. Clin Infect Dis. 2013 Jul. 57(2):176-84. [QxMD MEDLINE Link]. [Full Text].

177. Lin Y-C, Peterson ML. New insights into the prevention of staphylococcal infections and toxic shock syndrome. Expert Rev Clin Pharmacol. 2010. 3:753-767.

178. Huda T, Nair H, Theodoratou E, Zgaga L, Fattom A, El Arifeen S, et al. An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children. BMC Public Health. 2011 Apr 13. 11 Suppl 3:S27. [QxMD MEDLINE Link]. [Full Text].

179. Daum RS, Spellberg B. Progress Toward a Staphylococcus aureus Vaccine. Clin Infect Dis. 2012 Feb. 54(4):560-7. [QxMD MEDLINE Link].

180. Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T. Protection Against Staphylococcus aureus by Antibody to the Polyglycerolphosphate Backbone of Heterologous Lipoteichoic Acid. J Infect Dis. 2012 Apr. 205(7):1076-85. [QxMD MEDLINE Link].

181. Proctor RA. Challenges for a Universal Staphylococcus aureus Vaccine. Clin Infect Dis. 2012 Apr. 54(8):1179-86. [QxMD MEDLINE Link].

182. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, et al. Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis. J Infect Dis. 2012 Jun. 205(11):1688-96. [QxMD MEDLINE Link]. [Full Text].

183. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, et al. A Serologic Correlate of Protective Immunity Against Community-Onset Staphylococcus aureus Infection. Clin Infect Dis. 2013 Jun. 56(11):1554-61. [QxMD MEDLINE Link]. [Full Text].

184. McNeil JC, Hulten KG, Kaplan SL, Mahoney DH, Mason EO. Staphylococcus aureus Infections in Pediatric Oncology Patients: High Rates of Antimicrobial Resistance, Antiseptic Tolerance and Complications. Pediatr Infect Dis J. 2013 Feb. 32(2):124-8. [QxMD MEDLINE Link].

185. Creel AM, Durham SH, Benner KW, Alten JA, Winkler MK. Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children. Pediatr Crit Care Med. 2009 May. 10(3):323-7. [QxMD MEDLINE Link].

186. Vergnano S, Menson E, Smith Z, Kennea N, Embleton N, Clarke P. Characteristics of Invasive Staphylococcus aureus in United Kingdom Neonatal Units. Pediatr Infect Dis J. 2011 Oct. 30(10):850-4. [QxMD MEDLINE Link].

187. Menif K, Bouziri A, Khaldi A, Hamdi A, Belhadj S, Borgi A, et al. Community-associated methicillin-resistant Staphylococcus aureus infections in a pediatric intensive care unit. J Infect Dev Ctries. 2011 Aug 12. 5(8):587-91. [QxMD MEDLINE Link].

188. Heinrich N, Mueller A, Bartmann P, Simon A, Bierbaum G, Engelhart S. Successful management of an MRSA outbreak in a neonatal intensive care unit. Eur J Clin Microbiol Infect Dis. 2011 Jul. 30(7):909-13. [QxMD MEDLINE Link].

189. Woodlief RS, Markowitz JE. Unrecognized invasive infection in a neonate colonized with methicillin-resistant staphylococcus aureus. J Pediatr. 2009 Dec. 155(6):943-943.e1. [QxMD MEDLINE Link].

190. Arora P, Kalra VK, Pappas A. Multiple brain abscesses in a neonate after blood stream infection with methicillin-resistant Staphylococcus aureus. J Pediatr. 2012 Sep. 161(3):563-563.e1. [QxMD MEDLINE Link].

191. Niemann S, Ehrhardt C, Medina E, Warnking K, Tuchscherr L, Heitmann V, et al. Combined action of influenza virus and Staphylococcus aureus panton-valentine leukocidin provokes severe lung epithelium damage. J Infect Dis. 2012 Oct 1. 206(7):1138-48. [QxMD MEDLINE Link]. [Full Text].

192. Faden H, Gill S, Lesse A. Impact of Management and Bacterial Genomics on Outcomes of Staphylococcus aureus Bacteremia in Children. Clin Pediatr (Phila). 2011 Jun 17. [QxMD MEDLINE Link].

193. Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, et al. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis. 2012 Oct 17. 12:260. [QxMD MEDLINE Link]. [Full Text].

194. Sengupta A, Rand C, Perl TM, Milstone AM. Knowledge, Awareness, and Attitudes Regarding Methicillin-Resistant Staphylococcus Aureus among Caregivers of Hospitalized Children. J Pediatr. 2011 Mar. 158(3):416-21. [QxMD MEDLINE Link].

Elizabeth P Baorto, MD, MPH Director, Division of Pediatric Infectious Diseases, Atlantic Health System

Disclosure: Nothing to disclose.

David Baorto, MD, PhD Medical Knowledge Engineer, Department of Medical Informatics, Columbia University Medical Center

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD, FACP Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine

Larry I Lutwick, MD, FACP is a member of the following medical societies: American Association for the Advancement of Science, American Association for the Study of Liver Diseases, American College of Physicians, American Federation for Clinical Research, American Society for Microbiology, Infectious Diseases Society of America, Infectious Diseases Society of New York, International Society for Infectious Diseases, New York Academy of Sciences, Veterans Affairs Society of Practitioners in Infectious Diseases

Disclosure: Nothing to disclose.

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

José Rafael Romero, MD Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center

José Rafael Romero, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, New York Academy of Sciences, Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article